Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joyce F Liu

Showing results (31-40 of 105) with videos related to

Pageof 11
Sort By:
JCO Clinical Cancer Informatics|January 18, 2019
Technology Applications: Use of Digital Health Technology to Enable Drug DevelopmentJoyce F Liu, Jung-Min Lee, Ellie Strock, et al.
Gynecologic Oncology Reports|August 31, 2019
Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancerElizabeth K Lee, Zhenying Tan-Wasielewski, Ursula A Matulonis, et al.
Cancer Research|December 25, 2013
Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancersAlison M Karst, Paul M Jones, Natalie Vena, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2019
First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid TumorsJessica J Tao, Nicholas A Cangemi, Vicky Makker, et al.
Gynecologic Oncology|July 2, 2024
Improving the palliative-procedure decision-making process for patients with peritoneal carcinomatosis: A secondary analysisJaclyn A Wall, Rachel A Pozzar, Andrea C Enzinger, et al.
Gynecologic Oncology|May 24, 2019
Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancerJoyce F Liu, Kathryn P Gray, Alexi A Wright, et al.
Gynecologic Oncology Reports|July 18, 2025
Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcomaStephanie Cham, Niya Xiong, Nabihah Tayob, et al.
Gynecologic Oncology|May 11, 2020
Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisisBhavana Pothuri, Angeles Alvarez Secord, Deborah K Armstrong, et al.
Nucleic Acids Research|April 23, 2025
DirectHRD enables sensitive scar-based classification of homologous recombination deficiencyRuolin Liu, Eugenia Roberts, Heather A Parsons, et al.
Science Translational Medicine|March 11, 2016
Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironmentSuming Wang, Anna Blois, Tina El Rayes, et al.
Pageof 11

Showing results (31-40 of 105) with videos related to

Sort By:
Pageof 11
JCO Clinical Cancer Informatics|January 18, 2019
Technology Applications: Use of Digital Health Technology to Enable Drug DevelopmentJoyce F Liu, Jung-Min Lee, Ellie Strock, et al.
Gynecologic Oncology Reports|August 31, 2019
Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancerElizabeth K Lee, Zhenying Tan-Wasielewski, Ursula A Matulonis, et al.
Cancer Research|December 25, 2013
Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancersAlison M Karst, Paul M Jones, Natalie Vena, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2019
First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid TumorsJessica J Tao, Nicholas A Cangemi, Vicky Makker, et al.
Gynecologic Oncology|July 2, 2024
Improving the palliative-procedure decision-making process for patients with peritoneal carcinomatosis: A secondary analysisJaclyn A Wall, Rachel A Pozzar, Andrea C Enzinger, et al.
Gynecologic Oncology|May 24, 2019
Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancerJoyce F Liu, Kathryn P Gray, Alexi A Wright, et al.
Gynecologic Oncology Reports|July 18, 2025
Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcomaStephanie Cham, Niya Xiong, Nabihah Tayob, et al.
Gynecologic Oncology|May 11, 2020
Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisisBhavana Pothuri, Angeles Alvarez Secord, Deborah K Armstrong, et al.
Nucleic Acids Research|April 23, 2025
DirectHRD enables sensitive scar-based classification of homologous recombination deficiencyRuolin Liu, Eugenia Roberts, Heather A Parsons, et al.
Science Translational Medicine|March 11, 2016
Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironmentSuming Wang, Anna Blois, Tina El Rayes, et al.
Pageof 11